Europe
Before founding Zynex over two decades ago, Thomas Sandgaard was a man who had just moved to the U.S. from Denmark, starting in a one-bedroom apartment, only a humble few thousand dollars to his name.
France’s competition authority finedJ&K $29.6M on Wednesday after it ruled the company had deliberately slowed market access to generic copies of its painkiller Durogesic.
Takeover whispers boosted long-standing target Shire to the top of the FTSE 100 as the pharma firm’s shares rallied on hopes of a mega deal bringing shareholders an early Christmas present.
Fresenius now expects its planned takeover of Akorn, a U.S. maker of liquid generic drugs, to be completed in early 2018 rather than this year, a spokesman for Fresenius said on Tuesday.
Baillie Gifford and ORI Capital co-led the financing with significant new investments from Temasek and Cowen Healthcare Investments, alongside Juda Capital, Pavilion Capital, RTW Investments, Agent Capital, 4BIO Capital and existing investors F-Prime Capital and UCL Technology Fund.
The fact that Roche has separate R&D units has been the topic of second-guessing on the part of observers and analysts.
After completing a successful Phase 3 study for its novel semi-synthetic pleuromutilin antibiotic, Lefamulin, Nabriva released top-line results in September.
Roche’s patent dispute with Shire over the new haemophilia drug Hemlibra has escalated, with Shire filing a new motion in a U.S. court that Roche says aims to stop some patients from getting its medicine.
Now that we’ve got the bad news out of the way, we’re here to spread some Christmas cheer with the biggest clinical successes in biotech over the past 12 months.
Under terms of the deal, Boehringer has the option to acquire Autifony’s Kv3.1/3.2 positive modulator platform, which includes the company’s lead compound AUT00206.
PRESS RELEASES